Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
30 mai 2024 02h35 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 million in milestone payments from Centessa...
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
30 mai 2024 02h30 HE
|
Nxera Pharma
Expansion of existing partnership will utilize novel insights into causal biology within auto-immune disorders to identify novel targets for drug discovery Tokyo, Japan, Oxford and Cambridge,...
Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
09 mai 2024 02h35 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading...
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
09 mai 2024 02h30 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first...
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan
17 avr. 2024 03h09 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 17 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it has decided to issue new...
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
16 avr. 2024 02h30 HE
|
Nxera Pharma
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine BiosciencesSuccessful completion of...
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea
14 avr. 2024 19h30 HE
|
Nxera Pharma
PIVLAZ™ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH)PIVLAZ™ will become commercially available in South...
Nxera Pharma joins the World Orphan Drug Alliance
08 avr. 2024 02h30 HE
|
Nxera Pharma
Nxera Pharma to represent WODA in Japan and South Korea WODA offers a ‘one-stop’ solution for biopharma companies seeking to commercialize rare or orphan medicines across global markets ...
Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC
03 avr. 2024 02h47 HE
|
Nxera Pharma
Tokyo, Japan and Cambridge, UK, 3 April 2024 - Nxera Pharma (“Nxera” or “the Company”; TSE: 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Japan...
Nxera Pharma is the New Name for Sosei Group
31 mars 2024 19h30 HE
|
Nxera Pharma
New name expresses the Company’s vision to lead the next era of medicine - from Japan, for Japan, and by extension, to the world – and its mission to accelerate the development of life-changing...